ArticleBMC medical genomics2026
A novel androgen receptor gene splice site mutation induces aberrant mRNA splicing and internal in-frame deletion in androgen insensitivity syndrome.
Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Androgen insensitivity syndrome (AIS) is a disorder caused by pathogenic mutations in the androgen receptor (AR) gene, leading to androgen resistance and impaired sex differentiation in 46,XY individuals. Despite increasing recognition of AR mutations, the pathogenic mechanisms and genotype–phenotype correlations of many variants remain incompletely characterized. In this study, we identified a novel splice site mutation in the AR gene, c.2450-1G > A, in a 46,XY patient presenting with a female phenotype, including primary amenorrhea and classical features of AIS, confirmed by chromosomal analysis and ultrasonography. Functional validation using minigene splicing assays demonstrated that this variant disrupts normal splicing, leading to an aberrant transcript lacking 6 bp at the 5′ end of exon 7. This results in an aberrant in-frame transcript, c.2450_2455del, encoding a mutant protein with a three-amino acid deletion and a methionine insertion (p.Ile817_Val819delinsMet), while preserving the reading frame. In silico structural modeling suggested that this alteration may disturb the ligand-binding domain (LBD) conformation and receptor functionality. These findings highlight the pathogenic significance of splice-site variants in AR and provide mechanistic insight into AIS diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.